Literature DB >> 15228444

Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.

H Samaratunga1, K Khoo.   

Abstract

AIMS: To investigate whether prognosis in micropapillary urothelial carcinoma is related to the proportion of the micropapillary component (MPC), and to identify the immunohistochemical features of MPC. METHODS AND
RESULTS: This study presents a clinicopathological analysis of 20 patients with micropapillary urothelial carcinoma of the bladder with cystectomy specimens for evaluation. Tumours were stratified on the extent of MPC: focal, <10%; moderate, 10-50%; extensive, >50%; and this was correlated with tumour stage and prognosis. Sixteen males and four females were aged 56-81 years (mean 69 years). All cases had high-grade morphology in the micropapillary carcinoma and typical urothelial carcinoma. All cases with extensive MPC (n = 4) were of a high pathological stage (pT3 or pT4) and died of disease (DOD) or other causes. Eighty percent with moderate MPC (eight of 10 cases) were pT3 or pT4 and 50% DOD or are alive with disease. Eighty-four percent with focal MPC (five of six cases) were pT1 or pTa. In high-stage cases, the most invasive component was MPC. High-stage cases had an 85% risk of being advanced at presentation with micropapillary carcinoma. All pT2 or lower stage cases had micropapillary carcinoma on prior transurethral resections of bladder tumour (TURB). High-stage carcinomas had 30% and 54%, respectively, of surface MPC and urothelial carcinoma in situ, in comparison with 85% and 28% in lower stage carcinomas. Immunohistochemical staining was similarly positive in MPC and typical urothelial carcinoma with cytokeratin (CK)7, CK20, epithelial membrane antigen, carcinoembryonic antigen and cytokeratin 34betaE12. CA125 staining was seen only in MPC in 43% of cases.
CONCLUSIONS: Micropapillary urothelial carcinoma is a high-grade carcinoma in which the prognosis is related to the proportion and location of the MPC. Cases with moderate or extensive MPC are at high risk of being advanced at presentation. Cases with <10% MPC and surface MPC have a high chance of detection at an early stage. The morphology and immunohistochemical profile of the MPC suggest that it is a form of glandular differentiation in urothelial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228444     DOI: 10.1111/j.1365-2559.2004.01895.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  34 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

2.  Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.

Authors:  Simone Bertz; S Wach; H Taubert; R Merten; F S Krause; S Schick; O J Ott; E Weigert; O Dworak; C Rödel; R Fietkau; B Wullich; B Keck; A Hartmann
Journal:  Virchows Arch       Date:  2016-07-08       Impact factor: 4.064

3.  Clinical outcomes of cT1 micropapillary bladder cancer.

Authors:  Daniel L Willis; Mario I Fernandez; Rian J Dickstein; Sahil Parikh; Jay B Shah; Louis L Pisters; Charles C Guo; Samuel Henderson; Bogdan A Czerniak; H Barton Grossman; Colin P Dinney; Ashish M Kamat
Journal:  J Urol       Date:  2014-09-22       Impact factor: 7.450

4.  Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder.

Authors:  Massimiliano Spaliviero; Guido Dalbagni; Bernard H Bochner; Bing Ying Poon; Hongying Huang; Hikmat A Al-Ahmadie; Timothy F Donahue; Jennifer M Taylor; Joshua J Meeks; Daniel D Sjoberg; S Machele Donat; Victor E Reuter; Harry W Herr
Journal:  J Urol       Date:  2014-03-03       Impact factor: 7.450

5.  Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma.

Authors:  Tamara L Lotan; Huihui Ye; Jonathan Melamed; Xue-Ru Wu; Ie-Ming Shih; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

6.  Micropapillary carcinoma of the urinary bladder: a case report and review of the literature.

Authors:  Amel Trabelsi; Wided Stita; Rammeh Soumaya; Sarra Mestiri; Mehdi Jaidene; Moncef Mokni; Sadok Korbi
Journal:  Can Urol Assoc J       Date:  2008-10       Impact factor: 1.862

7.  Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer.

Authors:  Venu Chalasani; Joseph L Chin; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 8.  Micropapillary bladder cancer: current treatment patterns and review of the literature.

Authors:  Daniel L Willis; Thomas W Flaig; Donna E Hansel; Matthew I Milowsky; Robert L Grubb; Hikmat A Al-Ahmadie; Elizabeth R Plimack; Theresa M Koppie; David J McConkey; Colin P Dinney; Vanessa A Hoffman; Michael J Droller; Edward Messing; Ashish M Kamat
Journal:  Urol Oncol       Date:  2014-06-13       Impact factor: 3.498

9.  Immunohistochemical analysis of invasive micropapillary carcinoma pattern in four cases of gastric cancer.

Authors:  Yuji Ohtsuki; Naoto Kuroda; Shigeru Yunoki; Shinzo Murakami; Yuji Mizukami; Yuhei Okada; Mitsuko Iguchi; Gang-Hong Lee; Mutsuo Furihata
Journal:  Med Mol Morphol       Date:  2013-03-09       Impact factor: 2.309

10.  Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience.

Authors:  Pierre Heudel; Fadi El Karak; Nabil Ismaili; Jean-Pierre Droz; Aude Flechon
Journal:  BMC Urol       Date:  2009-06-17       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.